Actively Recruiting

All Genders
ID03291223

Gaucher Disease Outcome Survey (GOS) Registry of Patients with Gaucher Disease

Led by Shire · Updated on 2026-05-14

1257

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

The Gaucher Outcomes Survey (GOS) is an ongoing international observational registry for patients diagnosed with Gaucher Disease, regardless of their treatment status or type of treatment they receive. The registry aims to collect long-term data to better understand the natural history of Gaucher Disease and to evaluate the safety and long-term effectiveness of treatments like velaglucerase alfa. This study also seeks to provide a database to support evidence-based management of Gaucher Disease in real-life clinical settings. Participants in GOS are not given any experimental treatments as the study is observational. Patients undergo clinical assessments and receive care as determined by their own treating physicians. Enrollment was temporarily paused in some locations due to the COVID-19 pandemic but has since resumed in several countries. The registry includes patients of all ages and treatment types, tracking their health outcomes over many years. During the study, participants undergo regular clinical evaluations to monitor various health measures such as adverse events, infusion-related reactions, hemoglobin levels, platelet counts, liver and spleen volumes, and bone mineral density. These outcomes are followed from baseline through one year and can continue for up to 20 years. The long-term collection of data helps researchers understand treatment effects and disease progression in real-world practice while ensuring ongoing safety monitoring.

CONDITIONS

Brief Title

Gaucher Disease Outcome Survey (GOS)

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients of any age or gender with confirmed diagnosis (biochemical and/or genetic) of Gaucher Disease
  • Signed and dated written informed consent from the patient or, for patients under 18 years (under 16 years in the United Kingdom), their parent and/or legally authorized representatives
  • Assent of the minor where applicable
  • Legally authorized representatives are applicable for cognitively impaired patients
Not Eligible

You will not qualify if you...

  • Patients currently enrolled in ongoing blinded clinical trials involving drugs or devices

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 20 years

Participants with Gaucher Disease are observed over time to collect data on treatment outcomes and disease progression.

Periodic visits as determined by treating physicians and registry protocol

Trial Site Locations

Total: 1 location

1

Central Contact

Lexington, Massachusetts, United States, 02421

Actively Recruiting

Loading map...

Research Team

S

Shire Contact

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the...

Gaucher Disease

Actively Recruiting

9 locations

A Long-term Follow-up Study of Gaucher Disease

Gaucher Disease

Actively Recruiting

1 location

Drug Discovery for Parkinson's With Mutations in the GBA Gen...

Parkinson Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys.

Shoshana Revel-Vilk, Uma Ramaswami, Guillem Pintos-Morell...

https://pubmed.ncbi.nlm.nih.gov/40155993

Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry.

Deborah Elstein, Nadia Belmatoug, Bruno Bembi...

https://pubmed.ncbi.nlm.nih.gov/38930117